Drug intelligence / Profile preview

EG-014

Development stage: Preclinical
Lead developer: Enhanced Genomics

Overview

EG-014 is an investigational, preclinical-stage therapeutic candidate being developed by Enhanced Genomics for the treatment of inflammatory bowel disease (IBD). The candidate was identified using the company's proprietary GenLink™ 3D multi-omics platform, which maps three-dimensional genome folding to link non-coding genetic variants to disease-driving genes. By translating complex genetic data into high-confidence, genetically validated targets, Enhanced Genomics aims to develop highly effective therapies for autoimmune and inflammatory conditions. Specific details regarding the modality, molecular target, and mechanism of action of EG-014 have not been publicly disclosed.

Beyond the preview

Go deeper on EG-014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG-014.

Explore the full profile